BioNTech Q3 top-line up +135%

• BioNTech (NASDAQ:BNTX) Q3 results (€):
• Revenues: 67.5M (+135.2%).
• Net loss: (210M) (-597.7%); loss/share: (0.88) (-528.6%).
• Cash used in Operations: (262.7M) (-94.7%).
• Yesterday, BNTX and PFE's COVID-19 vaccine candidate, BNT162b2 demonstrated evidence of efficacy above 90%, at 7 days after the second dose against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.
• In addition to the primary endpoints, the final analysis will now include, with FDA approval, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose.
• On October 21, BioNTech and Pfizer initiated a Phase 1/2 clinical trial in Japan to evaluate safety, tolerability and immunogenicity of two doses separated by 21 days and a single dose of BNT162b2.
• BNTX and PFE have announced commercial supply agreements for more than 570M doses for 2020 and 2021, including options to purchase an additional 600M doses with multiple governments.
• Also, the company closed equity and debt financings and secured grant commitments of ~$1.2B (€1B) in combined gross proceeds, resulting in net cash receipts of $0.8B (€0.6B) in Q3.
• https://seekingalpha.com/news/3634321-biontech-q3-top-line-upplus-135-shares-continue-to-surge-on-covidminus-19-vaccine-news